Biovica Q1 Update: Capitalised but the launch is still not in full swing - Redeye

Biovica continues to increase 12m rolling IVD test sales in Q1 of SEK 0.93m (167% rolling 12m) and total net sales of SEK 2.6m after adding ROU & Pharma sales (test and services). Biovica is also progressing with a guaranteed rights issue at SEK 80m plus a SEK 42.2m Direct Share Issue (gross) and advancing the sales outlook based on Tempus AI in the Oncology segment, with a major partner in the IDN segment.

Länk till analysen i sin helhet: https://www.redeye.se/research/1127489/biovica-q1-update-capitalised-but-the-launch-is-still-not-in-full-swing?utm_source=finwire&utm_medium=RSS